×
English
हिंदी
ગુજરાતી
Home
My Feed
Remove Ads
Get Premium Content
Go Pro @₹99
Credit Cards
Instant Loans
Apply Now
Credit Score
Refer & Earn ₹500
Refer Now
Finance Tracker
Learning Curve
Fixed Deposits
Business Loan
Markets
Markets
FII & DII Activity
Corporate Action
Research Advice
Earnings
Technical Trends
Stock Deals
Intraday Large Deals
Bonds
Webinar
Pre Market
Stock Scanner
Sector Analysis
Unlisted Shares
Stock Updates
Monsoon Tracker
Seasonality Analysis
Crypto Dashboard
Web Stories
Tax Calculator
Forum
Gold Rate
Silver Rate
IFSC Code Finder
Storyboard18
IPO
Economic Indicators
Economic Calendar
Global Markets
US Markets
ETFs
Indian Indices
News
News
Tech/Startups
Auto
Research
Opinion
Politics
Personal Finance
EPF Guide
Real Estate
Portfolio
Watchlist
Personal Finance
Personal Finance
Loans
Fixed Deposit Comparison
Fixed Deposit Interest Calculator
Moneycontrol - SecureNow Health Insurance ratings
Mutual Funds
Mutual Funds
Performance Tracker
Top ranked funds
My Portfolio
Top performing Categories
Forum
New Fund Offers
MF Simplified
Commodities
Mutual Funds
Gold Rate
Silver Rate
Currencies
Cryptocurrency
Media
Live TV & Shows
Video
Podcast
Photos
Invest Now
Trade like Experts
Specials
Pharma Industry Conclave
Unlocking opportunities in Metal and Mining
Mutual Fund Summit 2025
Advanced Technical Charts
International
Get App
Be a
Pro
Home
PRO
Markets
News
Editor’s Picks
Tech
India
Learning Curve
Portfolio
Watchlist
Commodities
MF
Personal Finance
Forum
Videos
you are here:
Home
News
Ads
Expect Rs 280-285 crore of topline in Sorbitol segment: Gulshan Polyols
No plan to merge SPARC with Sun Pharma: Dilip Shanghvi
See Rs 400cr increase in top line over next few yrs: Hetero
Sun's margins may reduce to 30-32% post merger: Surajit Pal
Sun-Ranbaxy: Agency to monitor drug divestment, says CCI
Ranbaxy loses Valcyte exclusivity: An analysis
SC notice to Ranbaxy over adulterated drug; stock sinks 5%
Need to be watchful of FDA import alert pattern: Dandekar
'Doubt Ranbaxy claim that Mohali product filings not hit'
Ailing pharma sector needs uniform drug standards: Ranbaxy
'India to lead global growth; bet on financial services'
'Adulteration' defined differently in US and India: Ranbaxy
Setting things right, not aware of DCGI probe: Ranbaxy
Not impacted by Ranbaxy's negative news: Alembic Pharma
Will end 2012 with higher sales, profits: Ranbaxy
Ranbaxy to have 30% mkt share for Lipitor: PharmAsiaNews
Lipitor is biggest catalyst to Ranbaxy's growth: Expert
Blocking Ranbaxy's launch of cholesterol drug, where is the logic?
Ranbaxy to find a new CFO
What is Lupin's acquisition agenda for the future?
Ranbaxy, Merck call off anti-infectives deal
Home
Markets
Loans
SPIN
2
WIN
News
Portfolio